Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures
| Autor: | Marc Kottmaier, Tilko Reents, Verena Semmler, Hannah Pausch, Katharina Koch-Büttner, M. Telishevska, Isabel Deisenhofer, Christian Grebmer, M. Kornmayer, Gabriele Hessling, Roger Dillier, C. Kolb, Felix Bourier, Sonia Ammar-Busch, Bernhard M. Kaess, Amir Brkic, S. Lengauer, E. Rousseva, S. Brooks, Carsten Lennerz |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty Pyridines Radiofrequency ablation medicine.medical_treatment Activated clotting time Catheter ablation 030204 cardiovascular system & hematology law.invention Phenprocoumon Electrocardiography 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Edoxaban law Internal medicine Atrial Fibrillation Humans Medicine International Normalized Ratio 030212 general & internal medicine Atrial tachycardia Aged Radiofrequency Ablation medicine.diagnostic_test business.industry Anticoagulants Atrial fibrillation Middle Aged medicine.disease Thiazoles Treatment Outcome chemistry Pulmonary Veins Anesthesia Cardiology Female medicine.symptom Cardiology and Cardiovascular Medicine business Complication Factor Xa Inhibitors medicine.drug |
| Zdroj: | The American Journal of Cardiology. 121:445-449 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2017.11.015 |
| Popis: | Data about the safety of edoxaban in patients who underwent left atrial (LA) radiofrequency (RF) ablation procedures are lacking. This study sought to compare the safety of uninterrupted edoxaban with uninterrupted phenprocoumon administration during LA RF ablation for atrial fibrillation and atrial tachycardia. In total, 231 patients (mean age 64 ± 11years, male 71%) who underwent LA RF ablation under continuous oral anticoagulation (OAC) with edoxaban or phenprocoumon were included in the study. Patients on uninterrupted edoxaban (60 mg or 30 mg/day for at least 4 weeks) were matched for gender, age and type of arrhythmia with 2 patients on uninterrupted phenprocoumon (international normalized ratio 2 to 3). We identified 77 consecutive patients on edoxaban and n = 154 patients on phenprocoumon. Heparin was administered periprocedurally to achieve an activated clotting time of 280 to 300 seconds. No protamine was administered periprocedurally. The primary end point was a composite of bleeding, thromboembolic events, and death. The primary end point was met in 9 patients in the edoxaban group and in 22 patients in the phenprocoumon group (p = 0.69). No patient in either group died or had a thromboembolic complication. No major bleeding complication was observed in the edoxaban group, whereas one was found in 1 patient in the phenprocoumon group (p ≥0.99). Minor bleeding complications occurred in 9 patients (12%) in the edoxaban group and in 21 patients (14%) in the phenprocoumon group (p = 0.84). Uninterrupted OAC with edoxaban appeared to be as safe as uninterrupted OAC with phenprocoumon in patients who underwent LA RF ablation procedures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect